11/05/2019 01:33:03

NOTICE TO GPB CAPITAL HOLDINGS INVESTORS – Klayman & Toskes, P.A. Files FINRA Arbitration Claim seeking $1,000,000 on Behalf of Investors Who Sustained Losses on GPB Notes

BOCA RATON, Fla., May 10, 2019 (GLOBE NEWSWIRE) -- The Securities Arbitration Law Firm of Klayman & Toskes, P.A. ("K&T") (https://www.nasd-law.com) announced today that it has filed a claim against Royal Alliance Associates, Inc. (“Royal Alliance”) on behalf of investors who sustained losses from the purchase of private placement securities of GPB Capital Holdings (“GPB”) in the form of notes.

According to the claim, the Investors instructed Royal Alliance to invest their hard-earned savings and inheritance in a conservative manner, protecting their principal and present income. Instead, Royal Alliance concentrated a substantial portion of the investors’ assets into illiquid alternative investments and private placements, including securities of GPB. Royal Alliance’s actions caused the investors to lose over $1,000.000.00 of their hard-earned savings and inheritance.

More than 60 brokerage firms sold $1.5 billion of high-risk private placement GPB funds, including Royal Alliance Associates Inc., Sagepoint Financial Inc., FSC Securities Corp., and Woodbury Financial Services Inc. The private placement GPB funds of GPB Automotive Portfolio and GPB Holdings II raised $622.1 million and $645.8 million respectively. Since flagrantly missing its April 30, 2018, deadline to register the raised funds, GPB’s offices in Manhattan have been searched by the FBI. The SEC also issued a subpoena to GPB seeking information. Additionally, GPB’s auditor recently resigned over the perceived risks of the ongoing investigations.

The sole purpose of this release is to investigate the sales practices and financial misconduct of brokerage firms and financial advisors in connection with the sale of GPB to their customers. Investors who purchased these investments are encouraged to contact Lawrence L. Klayman, Esq. of Klayman & Toskes, P.A.  at (888) 997-9956, or visit our website at www.nasd-law.com

About Klayman & Toskes, P.A.

K&T is a leading national securities law firm which practices exclusively in the field of securities arbitration and litigation, on behalf of retail and institutional investors throughout the world in large and complex securities matters. The firm represents high net-worth, ultra-high-net-worth, and institutional investors, such as non-profit organizations, unions, public and multi-employer pension funds. K&T has office locations in California, Florida, New York and Puerto Rico.

Destination: https://nasd-law.com/notice-to-gpb-capital-holdings-investors-klayman-toskes-p-a-files-finra-arbitration-claim-seeking-1000000-00-on-behalf-of-investors-who-sustained-losses-on-gpb-notes/

Contact:

Klayman & Toskes, PA

Lawrence L. Klayman, Esq.

888-997-9956

lklayman@klaymantoskes.com

www.nasd-law.com

KT Logo.jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
13 Jun
PNDORA
Hvad er det for noget eklatant ævl.Hvis man sammenholder de store fondes indtog på det danske aktiem..
24
13 Jun
PNDORA
Jeg er meget imponeret over Jyske bank og i særdeleshed analytikkeren Janne Vincent Kjær. Kunne rest..
20
12 Jun
PNDORA
er i dag ude med en dødsdoms artikel omkring Pandora. Artiklen er skrevet af en velanset analytiker,..
17
12 Jun
NOVO-B
Novo Nordisk aktien er d.d. steget med 120 kr. siden d. 25. nov. 2016. Dvs. fra 226 til 346 kr. 💪 ..
17
15 Jun
PNDORA
Udover den samme analyse blev offentligjort for snart 3 uger siden er det da glimrende at man igen, ..
16
10 Jun
VELO
https://clinicaltrials.gov/ct2/show/study/NCT03979365 Bliver også spændene, at se om Envarsus sna..
15
15 Jun
PNDORA
Mit take på Pandora: Tidligere ledelse ønskede at væksten for vækstens skyld. Det har vist sig, a..
14
13 Jun
PNDORA
Nå du mener som IKEA, KIA, Hyundai, Harald Nyborg, Jysk og alle de andre hvor ingen vil handle..;)Må..
13
13 Jun
 
Kildevand på flaske ligeledes. Forbyd det. Kildevand, der fragtes fra Frankrig og  Italien til Danma..
13
12 Jun
PNDORA
Uden at have noget kendskab til Per Hansen artiklen, så kan jeg med sikkerhed sige, at din kommentar..
13

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
REV DEADLINE: Rosen, a Highly Ranked Law Firm, Reminds Revlon, Inc. Investors of Important July 15th Deadline in Securities Class Action – REV
2
Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
3
Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
4
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress
5
Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 June 2019 10:50:05
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB4 - 2019-06-16 11:50:05 - 2019-06-16 10:50:05 - 1000 - Website: OKAY